

National Practitioner Data Bank Set to Change

BY JOYCE FRIEDEN
Senior Editor

PHILADELPHIA — A new service being offered by the National Practitioner Data Bank will make it easier for hospitals and other institutions to find out when a physician with privileges at their institution has had a data bank report filed on him or her by another entity.

The new program, called the Proactive Disclosure Service, is expected to start next spring, according to Shirley Jones, senior policy analyst at the Health Resources and Services Administration, Rockville, Md., the agency that runs the data bank.

The service allows the entity—a hospital or other facility—to register all practitioners who could potentially be subjects of data bank reports.

“Then, if the data bank gets a report on that practitioner, the data bank will automatically send the report to that entity,” Ms. Jones explained at the annual meeting of the American Health Lawyers Association. She added that the new program is “an alternative to, not a replacement for, the current querying service.”

There will be a small charge to the facility for each person it registers, probably around \$3 per practitioner, she said. Different entities can register the same practitioner.

Another change is a proposed regulation known as Section 1921, which will expand the data bank’s reach, Ms. Jones continued.

“Section 1921 will expand the data that’s in the data bank,” she said. “State licensing authorities must [now] report all adverse licensing actions about all practitioners,” not just physicians and dentists.

That means that hospitals and other organizations can query the data bank on other health professionals such as nurses, respiratory therapists, and massage therapists, she said.

Another part of Section 1921 would require peer review organizations to report negative actions taken against individual practitioners.

However, she noted, quality improvement organizations would be exempt from that requirement under the proposed rule.

When it published the proposed rule earlier this year in the Federal Register, the Health Resources and Services Administration explained why it is exempting quality improvement organizations.

“First, the critical mission of the [quality improvement organization] program is its focus on maintaining collaborative relationships with providers and practitioners to improve the quality of health care

services delivered to Medicare beneficiaries,” the agency noted.

“The reporting of [quality improvement organization] sanction recommendations to the National Practitioner Data Bank will significantly interfere with the progress that has been made toward this goal and will substantially reduce the ability of quality improvement organizations to carry out their statutory and contractual obligations,” according to the Health Resources and Services Administration.

The agency also expressed concern that requiring quality improvement organizations to report recommended sanctions to the data bank “may create misconceptions about the meaning of quality improvement organizations sanction recommendations,” since they are only recommendations and may not always be acted on. The agency is still reviewing comments it has received on the proposed rule.

In addition to the new regulations that

it is proposing, the data bank also has developed a compliance program to make sure that it is getting all the reports it should.

For example, data bank officials compare actions that have been documented on state licensing board Web sites with information that is in the data bank.

In addition, data bank staff look at newspapers, magazines, and public media “to see if we’re missing something,” Ms. Jones said. ■

Peer review organizations would have to report negative actions against practitioners, but quality improvement organizations would be exempt.



new

Introducing Levemir®: a long-acting basal insulin with a light touch

New Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations. Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision.

Concomitant oral antidiabetes treatment may require adjustment.
Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

new
Levemir®
insulin detemir (rDNA origin) injection
Lighter years ahead





Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S.
© 2006 Novo Nordisk Inc. 130299R1 May 2006